{"organizations": [], "uuid": "f40f550027e2c566a8ee5dfee32c118b33c87a12", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-regenxbio-and-avexis-announce-expa/brief-regenxbio-and-avexis-announce-expansion-of-relationship-for-spinal-muscular-atrophy-treatments-idUSFWN1P30PJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.992, "site_type": "news", "published": "2018-01-08T21:08:00.000+02:00", "replies_count": 0, "uuid": "f40f550027e2c566a8ee5dfee32c118b33c87a12"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-regenxbio-and-avexis-announce-expa/brief-regenxbio-and-avexis-announce-expansion-of-relationship-for-spinal-muscular-atrophy-treatments-idUSFWN1P30PJ", "ord_in_thread": 0, "title": "BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments", "locations": [], "entities": {"persons": [{"name": "avexis", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "avexis inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Avexis Inc:\n* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY\n* REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS\n* REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIOâ€˜S CONSENT\n* REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA\n* REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:08:00.000+02:00", "crawled": "2018-01-09T16:57:49.012+02:00", "highlightTitle": ""}